iifl-logo

Dr Reddys Laboratories Ltd Annually Results

1,228.5
(0.35%)
May 21, 2025|01:29:56 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021

Gross Sales

32,553.5

27,916.4

24,587.9

21,439.1

18,972.2

Excise Duty

0

0

0

0

0

Net Sales

32,553.5

27,916.4

24,587.9

21,439.1

18,972.2

Other Operating Income

90.4

94.7

81.8

106.1

75.3

Other Income

1,119

909

1,092.5

554.7

339.4

Total Income

33,762.9

28,920.1

25,762.2

22,099.9

19,386.9

Total Expenditure

24,096.8

20,078

18,320.7

17,777.5

15,177.6

PBIDT

9,666.1

8,842.1

7,441.5

4,322.4

4,209.3

Interest

282.9

171.1

142.8

95.8

97

PBDT

9,383.2

8,671

7,298.7

4,226.6

4,112.3

Depreciation

1,703.7

1,470

1,250.2

1,165.2

1,228.8

Minority Interest Before NP

0

0

0

0

0

Tax

2,258.1

1,945.9

814.4

1,101.3

817.2

Deferred Tax

-303.8

-322.8

726.8

-222.4

114.7

Reported Profit After Tax

5,725.2

5,577.9

4,507.3

2,182.5

1,951.6

Minority Interest After NP

70.1

0

0

0

0

Net Profit after Minority Interest

5,655.1

5,577.9

4,507.3

2,182.5

1,951.6

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

5,655.1

5,577.9

4,507.3

2,182.5

1,951.6

EPS (Unit Curr.)

67.89

335.22

271.47

131.57

117.67

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

800

800

800

600

500

Equity

83.4

83.4

83.3

83.2

83.2

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

29.69

31.67

30.26

20.16

22.18

PBDTM(%)

28.82

31.06

29.68

19.71

21.67

PATM(%)

17.58

19.98

18.33

10.17

10.28

Dr Reddys Labs: Related NEWS

Dr. Reddy’s Receives Two USFDA Observations for New York API Manufacturing Plant
18 May 2025|07:17 PM

Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.

Read More
Dr Reddy’s Q4 Profit Jumps 22% to ₹1,594 Crore
12 May 2025|01:00 PM

The board has recommended a final dividend of ₹8 per equity share for FY 2024–25

Read More
Top Stocks for Today - 12th May 2025
12 May 2025|09:32 AM

Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.

Read More
Dr. Reddy’s Laboratories Sells 14 ANDAs to Senores Pharma
5 Mar 2025|11:05 AM

Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.

Read More
Top Stocks for - 27th February 2025
26 Feb 2025|09:22 PM

Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.

Read More
Dr Reddy’s Hyderabad API Unit Gets USFDA VAI Classification
25 Feb 2025|08:42 PM

Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore. 

Read More
Dr Reddy’s Laboratories Q3 net profit zooms ~3%
24 Jan 2025|10:23 AM

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

Read More
Top Stocks for Today - 24th January 2025
24 Jan 2025|07:50 AM

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Read More
Top Stocks for today - 6th December 2024
6 Dec 2024|09:14 AM

Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.

Read More
Dr Reddy’s launches first immuno-onco drug in India
28 Nov 2024|03:43 PM

Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTOR

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.